Fig. 3
From: Antibody-drug conjugates in breast cancer: current evidence and future directions
Pivotal clinical trials of ADCs in breast cancer according to different agents and treatment settings. Data cutoff date, January 31, 2025. T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; SG, sacituzumab govitecan; Dato-DXd, datopotamab deruxtecan; P, pertuzumab; TCbHP, docetaxel-carboplatin-trastuzumab-pertuzumab; H, trastuzumab; THP, taxane-trastuzumab-pertuzumab, TH, paclitaxel-trastuzumab; SOC, standard of care; TPC, treatment of physician’s choice; Ana, anastrozole; Ate, atezolizumab; AC, anthracycline-cyclophosphamide; Pem, pembrolizumab; Dur, durvalumab